Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00350974 · ClinicalTrials.gov registry record

ADMA Levels in End-Stage Renal Disease

A clinical trial, sponsored by University of Michigan.

Completed
Registry status
61
Enrollment target

NCT00350974: Completed study, sponsored by University of Michigan.

NCT00350974 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00350974 has completed, sponsored by University of Michigan.

COMPLETED
Registry status
61 participants
Enrollment target

Study Summary

Asymmetric dimethylarginine, ADMA, in plasma, is significantly elevated in patients with renal disease and associated with cardiovascular morbidity and mortality. We found that whole blood (WB) possesses the metabolic pathways required for both the generation and elimination of ADMA and we have developed ex vivo methods to assess the WB accumulation of ADMA in humans. The over-arching hypothesis is that dysregulation of ADMA metabolic pathways leads to greater ADMA whole blood content and greater capacity to accumulate ADMA, which 1) is not reflected by plasma levels and 2) is a better predictor of cardiovascular outcome than plasma levels in end-stage renal disease (ESRD). The following specific aims will be pursued to characterize whole blood ADMA in ESRD: 1. Compare and contrast baseline free plasma ADMA and total whole blood (free plus protein-incorporated) ADMA concentrations in ESRD patients, matched hypertensive controls and a normal population. 2. Determine the capacity of WB to accumulate (the net balance of generation and elimination) ADMA in ESRD patients, matched hypertensive controls and a normal population. We will use state-of-the-art, high performance liquid chromatography techniques to measure ADMA levels in plasma and whole blood. Samples for ADMA measurements will be obtained from subjects with end-stage renal disease immediately before their dialysis treatments. Samples will also be obtained from volunteers without kidney disease. This group will be matched to the end-stage renal volunteers by age, gender and ethnicity. These volunteers will also be matched for the presence of hypertension and diabetes. The third group will consist of a normal population to measure the normal levels of ADMA and compare to the other two groups. There is growing evidence to support a pathological role of ADMA in humans. These experiments will enhance our understanding of how ADMA is processed in the human body and how it is associated with kidney disease. Potent

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2006-07
Est. Completion 2007-03-08
University of Michigan

1,327 total trials

What the finished NCT00350974 record still lists

NCT00350974 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 61 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT00350974 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00350974 about?

NCT00350974 is a clinical study titled "ADMA Levels in End-Stage Renal Disease". Asymmetric dimethylarginine, ADMA, in plasma, is significantly elevated in patients with renal disease and associated with cardiovascular morbidity and mortality. We found that whole blood (WB) possesses the metabolic pathways required for both the generation and elimination of ADMA and we have deve...

What is the current status of trial NCT00350974?

This trial is currently completed. The enrollment target is 61 participants. The study started on 2006-07. Estimated completion is 2007-03-08.

Who is sponsoring clinical trial NCT00350974?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04115306 · 61 participants · Phase 1

    Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

  • NCT05070845 · 61 participants · Phase 2

    Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

  • NCT05187832 · 61 participants · Phase 1

    A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

  • NCT05269316 · 61 participants · Phase 1

    Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00350974, the US trial registry maintained by the National Library of Medicine. NCT00350974 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.